LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

12.98 7.01

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.16

Max

13.03

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.4M -14M
Pelnas, tenkantis vienai akcijai	-0.15
Darbuotojai	37
EBITDA	-2.7M -15M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+159.23% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-339M 1B
Ankstesnė atidarymo kaina	5.97
Ankstesnė uždarymo kaina	12.98

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-21 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164 Million

2026-05-21 16:49; UTC

Uždarbis

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

2026-05-21 16:26; UTC

Pagrindinės rinkos jėgos

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

2026-05-21 23:51; UTC

Rinkos pokalbiai

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

2026-05-21 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

2026-05-21 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164M

2026-05-21 21:53; UTC

Uždarbis

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

2026-05-21 21:02; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

2026-05-21 20:55; UTC

Uždarbis

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

2026-05-21 20:30; UTC

Karštos akcijos

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

2026-05-21 20:20; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-21 20:20; UTC

Rinkos pokalbiai

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Adj EPS 3c >BULL

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Rev $159.9M >BULL

2026-05-21 20:18; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Easing in Early May -- Market Talk

2026-05-21 20:18; UTC

Uždarbis

Webull 1Q Loss/Shr 4c

2026-05-21 19:43; UTC

Rinkos pokalbiai

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-21 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

2026-05-21 18:58; UTC

Uždarbis

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

2026-05-21 18:15; UTC

Rinkos pokalbiai

Gold Higher For Second Consecutive Day -- Market Talk

2026-05-21 17:40; UTC

Rinkos pokalbiai

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

2026-05-21 17:04; UTC

Rinkos pokalbiai

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

2026-05-21 17:01; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

2026-05-21 16:20; UTC

Rinkos pokalbiai

Uždarbis

Stellantis Targets Distant but Constructive -- Market Talk

2026-05-21 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

159.23% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD 159.23%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.